REVIEW PAPER
Adalimumab – the first fully human monoclonal antibody used in the treatment of rheumatoid arthritis
More details
Hide details
Online publication date: 2008-07-09
Reumatologia 2008;46(3):151-158
KEYWORDS
ABSTRACT
Rheumatoid arthritis is a systemic inflammatory disease leading to joint deformation and multiorgan dysfunction. Adalimumab belongs to a new class of antirheumatic drugs. This article gives a systematic review of data supporting the efficacy of adalimumab in the treatment of rheumatoid arthritis.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (
https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.